Biogen IDEC Inc. (BIIB-Q)
NASDAQ:BIIB
130.71
0.61
(0.46%) 1d
Financials
Technical Analysis
Related posts
Friday rally cap choppy weakHot inflation data triggers sell-offTSX edges up, but Wall St. fear ratesThis summary was created by AI, based on 1 opinions in the last 12 months.
Biogen IDEC Inc. (BIIB-Q) has received critical reviews from various experts, with a notable sentiment highlighting dissatisfaction with its product offerings. Many reviewers express that the company is struggling to keep pace with its competitors, who are allegedly outshining Biogen in terms of performance and innovation. This poor perception may be attributed to a lack of robust new releases or advancements in their existing therapies, leading to concerns about their future prospects in the biopharmaceutical landscape. Overall, these reviews suggest a troubling outlook for Biogen, as it appears to be falling behind in a rapidly evolving industry where staying ahead is crucial for success and investor confidence.
(A Top Pick Nov 26/20, Up 26.1%)Stochchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CIEN has gapped up through the $305 target. To be disciplined, we recommend trailing up the stop (from $180) to $305. If triggered, this would all but guarantee a minimum investment return over 26%.
Stockchase Research Editor: Michael O'Reilly BIIB has been on a roller-coaster. When the FDA announced a priority review of a new Alzheimer's drug, it stock soared to $360. When the review failed to approve the drug in the first go-round, the stock plunged to under $250 -- so it goes with drug manufacturers. Its MS drugs continue to do well and it is working on treatments for Parkinson's disease as well. Trading at 8x earnings, it is cheap compared to peers at 30x. We would buy this with a $180 stop-loss looking to achieve $305 -- 26% upside. Yield 0%. (Analysts’ price target is $305.90)
https://www.pmlive.com/pharma_news/fda_sets_november_date_for_expert_panel_review_of_biogens_aducanumab_1351831 Until February 2020, Biogen's FDA results of an Alzheimer drug was the healthcare event of the year (then Covid hit). Novartis and other players are starting to compete here, though. He owned Biogen some years ago. He was on a panel which was split over whether Biogen would get FDA approval on Nov. 6. Regardless, this is a high-risk play; this could pop 35-50% up or down. The risk/return is too much for him. The drug has a checkered past and so far there is no effective Alzheimer's drug, but if it works it will be huge for the company and society.
Biogen IDEC Inc.(BIIB-Q) Rating
Ranking : 3 out of 5
Bullish - Buy Signals / Votes : 0
Neutral - Hold Signals / Votes : 1
Bearish - Sell Signals / Votes : 1
Total Signals / Votes : 2
Biogen IDEC Inc.(BIIB-Q) Frequently Asked Questions
What is Biogen IDEC Inc. stock symbol?
Biogen IDEC Inc. is a American stock, trading under the symbol BIIB-Q on the NASDAQ (BIIB). It is usually referred to as NASDAQ:BIIB or BIIB-Q
Is Biogen IDEC Inc. a buy or a sell?
In the last year, 2 stock analysts published opinions about BIIB-Q. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Biogen IDEC Inc..
Is Biogen IDEC Inc. a good investment or a top pick?
Biogen IDEC Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Biogen IDEC Inc..
Why is Biogen IDEC Inc. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Biogen IDEC Inc. worth watching?
2 stock analysts on Stockchase covered Biogen IDEC Inc. In the last year. It is a trending stock that is worth watching.
What is Biogen IDEC Inc. stock price?
On 2025-04-03, Biogen IDEC Inc. (BIIB-Q) stock closed at a price of $130.71.
Not impressed with products. Competitors out performing.